FDA NDC Directory · JSON-LD · Markdown
NDC 60492-0075 · PLASMA DERIVATIVE · LIQUID
| Generic name | Botulism Antitoxin Heptavalent |
|---|---|
| Labeler / Manufacturer | Emergent BioSolutions Canada Inc |
| Marketing category | Biologic License Application · App BLA125462 |
| Dosage form / route | LIQUID · INTRAVENOUS |
| Active ingredients | EQUINE BOTULINUM NEUROTOXIN A IMMUNE FAB2 (4500 [iU]/10mL) EQUINE BOTULINUM NEUROTOXIN B IMMUNE FAB2 (3300 [iU]/10mL) EQUINE BOTULINUM NEUROTOXIN C IMMUNE FAB2 (3000 [iU]/10mL) EQUINE BOTULINUM NEUROTOXIN D IMMUNE FAB2 (600 [iU]/10mL) EQUINE BOTULINUM NEUROTOXIN E IMMUNE FAB2 (5100 [iU]/10mL) EQUINE BOTULINUM NEUROTOXIN F IMMUNE FAB2 (3000 [iU]/10mL) EQUINE BOTULINUM NEUROTOXIN G IMMUNE FAB2 (600 [iU]/10mL) |
| Marketing started | 20130301 |
| Package count | 2 |
Source: openFDA. Public-domain (CC0).